Loading clinical trials...
Loading clinical trials...
Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis
This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after multiple doses of mirikizumab. The study will last about 23 weeks for each participant. Screening must be completed within 4 weeks prior to study start.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Anaheim Clinical Trials, LLC
Anaheim, California, United States
Avail Clinical Research LLC
DeLand, Florida, United States
High Point Clinical Trials Center
High Point, North Carolina, United States
Start Date
October 23, 2018
Primary Completion Date
October 28, 2019
Completion Date
October 28, 2019
Last Updated
January 29, 2024
29
ACTUAL participants
Drug Cocktail
DRUG
Mirikizumab
DRUG
Lead Sponsor
Eli Lilly and Company
NCT07449234
NCT07116967
NCT07250802
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions